137 related articles for article (PubMed ID: 12010239)
1. 18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse.
Sanchez D; Zudaire JJ; Fernandez JM; Lopez J; Arocena J; Sanz G; Gimenez M; Rosell D; Robles JE; Berian JM
BJU Int; 2002 Jun; 89(9):912-6. PubMed ID: 12010239
[TBL] [Abstract][Full Text] [Related]
2. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours.
Spermon JR; De Geus-Oei LF; Kiemeney LA; Witjes JA; Oyen WJ
BJU Int; 2002 Apr; 89(6):549-56. PubMed ID: 11942962
[TBL] [Abstract][Full Text] [Related]
3. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group.
Oechsle K; Hartmann M; Brenner W; Venz S; Weissbach L; Franzius C; Kliesch S; Mueller S; Krege S; Heicappell R; Bares R; Bokemeyer C; de Wit M;
J Clin Oncol; 2008 Dec; 26(36):5930-5. PubMed ID: 19018083
[TBL] [Abstract][Full Text] [Related]
4. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse.
Hain SF; O'Doherty MJ; Timothy AR; Leslie MD; Harper PG; Huddart RA
Br J Cancer; 2000 Oct; 83(7):863-9. PubMed ID: 10970686
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors.
Tsatalpas P; Beuthien-Baumann B; Kropp J; Manseck A; Tiepolt C; Hakenberg OW; Burchert W; Franke WG; Wirth MP
Urol Int; 2002; 68(3):157-63. PubMed ID: 11919460
[TBL] [Abstract][Full Text] [Related]
6. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours.
Lassen U; Daugaard G; Eigtved A; Højgaard L; Damgaard K; Rørth M
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):396-402. PubMed ID: 12634968
[TBL] [Abstract][Full Text] [Related]
7. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Bares R; Claussen CD; Kanz L; Bokemeyer C
Cancer; 2002 May; 94(9):2353-62. PubMed ID: 12015760
[TBL] [Abstract][Full Text] [Related]
8. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group.
Huddart RA; O'Doherty MJ; Padhani A; Rustin GJ; Mead GM; Joffe JK; Vasey P; Harland SJ; Logue J; Daugaard G; Hain SF; Kirk SJ; MacKewn JE; Stenning SP;
J Clin Oncol; 2007 Jul; 25(21):3090-5. PubMed ID: 17634488
[TBL] [Abstract][Full Text] [Related]
9. Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors.
Fernandez EB; Moul JW; Foley JP; Colon E; McLeod DG
Urology; 1994 Oct; 44(4):548-52. PubMed ID: 7941194
[TBL] [Abstract][Full Text] [Related]
10. Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow up.
Karapetis CS; Strickland AH; Yip D; Steer C; Harper PG
Intern Med J; 2003; 33(9-10):427-35. PubMed ID: 14511195
[TBL] [Abstract][Full Text] [Related]
11. The role of
Hung TJ; McLean L; Mitchell C; Pascoe C; Lawrentschuk N; Murphy DG; Iravani A; Singh D; Hofman MS; Zidan L; Akhurst T; Lewin J; Hicks RJ
Cancer Imaging; 2019 May; 19(1):28. PubMed ID: 31142361
[TBL] [Abstract][Full Text] [Related]
12. [Fluorodeoxyglucose (FDO) positron emission tomography (PET) in testicular germ cell tumors in adults: preliminary French clinical evaluation, development of the technique and its clinical applications].
Maszelin P; Lumbroso J; Theodore C; Foehrenbach H; Merlet P; Syrota A
Prog Urol; 2000 Dec; 10(6):1190-9. PubMed ID: 11217558
[TBL] [Abstract][Full Text] [Related]
13. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?--Results of a study in 50 patients.
Cremerius U; Wildberger JE; Borchers H; Zimny M; Jakse G; Günther RW; Buell U
Urology; 1999 Nov; 54(5):900-4. PubMed ID: 10565755
[TBL] [Abstract][Full Text] [Related]
14. FDG-PET evaluation of retroperitoneal metastases of testicular cancer before and after chemotherapy.
Reinhardt MJ; Müller-Mattheis VG; Gerharz CD; Vosberg HR; Ackermann R; Müller-Gärtner HW
J Nucl Med; 1997 Jan; 38(1):99-101. PubMed ID: 8998160
[TBL] [Abstract][Full Text] [Related]
15. 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy.
Johns Putra L; Lawrentschuk N; Ballok Z; Hannah A; Poon A; Tauro A; Davis ID; Hicks RJ; Bolton DM; Scott AM
Urology; 2004 Dec; 64(6):1202-7. PubMed ID: 15596197
[TBL] [Abstract][Full Text] [Related]
16. Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling.
Sugawara Y; Zasadny KR; Grossman HB; Francis IR; Clarke MF; Wahl RL
Radiology; 1999 Apr; 211(1):249-56. PubMed ID: 10189480
[TBL] [Abstract][Full Text] [Related]
17. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].
Pfannenberg AC; Oechsle K; Kollmannsberger C; Dohmen BM; Bokemeyer C; Bares R; Vontheim R; Claussen CD
Rofo; 2004 Jan; 176(1):76-84. PubMed ID: 14712410
[TBL] [Abstract][Full Text] [Related]
18. Fluorodeoxyglucose PET in the initial staging of germ cell tumours.
Hain SF; O'Doherty MJ; Timothy AR; Leslie MD; Partridge SE; Huddart RA
Eur J Nucl Med; 2000 May; 27(5):590-4. PubMed ID: 10853816
[TBL] [Abstract][Full Text] [Related]
19. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors.
Aprikian AG; Herr HW; Bajorin DF; Bosl GJ
Cancer; 1994 Aug; 74(4):1329-34. PubMed ID: 8055456
[TBL] [Abstract][Full Text] [Related]
20. FDG PET for detection and therapy control of metastatic germ cell tumor.
Cremerius U; Effert PJ; Adam G; Sabri O; Zimmy M; Wagenknecht G; Jakse G; Buell U
J Nucl Med; 1998 May; 39(5):815-22. PubMed ID: 9591582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
